Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01508949
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
  • placebo — DRUG
    Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

Study Details

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Key Dates

Start date
Jun 30, 2001
Status verified
Oct 2023
Primary completion
Mar 31, 2002
Completion
Mar 31, 2002

Study Design

Enrollment
35 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in weight

Related Studies